EGL-001 (EGL-121)

First-in-human Trial of EGL-001 in Patients with Selected Advanced And/·or Metastatic Solid Tumors
  • Open at Paris since : 22/10/2024
  • Target : Adult
  • Phase : Phase I/II

Trial description

To evaluate the safety, tolerability,;and dose-limiting toxicities (DLTs);and the maximum tolerated dose;(MTD) leading to the recommended;Phase 2 doses (RP2Ds) of EGL-001;monotherapy or in combination with;an anti-PD(L)-1 in adult patients with;selected advanced/metastatic solid;tumors.;To evaluate preliminary efficacy as;defined by objective response rate;(ORR), according to Response;Evaluation Criteria in Solid Tumors;(RECIST) Version 1.1 for the RP2D;of EGL-001 monotherapy and/or in;combination with an anti-PD(L)-1 in;adult patients with selected;advanced/metastatic solid tumors.
Url of the trial

Main investigator

CHRISTOPHE LE TOURNEAU

Professeur - Médecin

Contact
Default